Kim R Tsuchimoto sold $456k of MNPR
Chief Financial Officer at Monopar Therapeutics. 4,090 shares at an average of $111.39, traded Aug 26, 2026, filed Aug 27, 2026.
Score components
- +15RoleDirector
- +17Trade size$456k at market
- +10Share of holdings soldSold 36% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-26-029116, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | SOpen-market sale Common Stock10b5-1 | -485 | $108.83 | $53k | 11,001 | Aug 27, 2026 |
| Aug 26, 2026 | SOpen-market sale Common Stock10b5-1 | -615 | $109.56 | $67k | 10,386 | Aug 27, 2026 |
| Aug 26, 2026 | SOpen-market sale Common Stock10b5-1 | -700 | $110.65 | $77k | 9,686 | Aug 27, 2026 |
| Aug 26, 2026 | SOpen-market sale Common Stock10b5-1 | -1,098 | $111.84 | $123k | 8,588 | Aug 27, 2026 |
| Aug 26, 2026 | SOpen-market sale Common Stock10b5-1 | -602 | $112.93 | $68k | 7,986 | Aug 27, 2026 |
| Aug 26, 2026 | SOpen-market sale Common Stock10b5-1 | -590 | $113.84 | $67k | 7,396 | Aug 27, 2026 |
Related signals
Other insiders at Monopar Therapeutics and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Monopar Therapeutics | Christopher M Starr director | $659k 8,400 shares | -62% | |
| 28Weak | Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $2.6M 29,056 shares | -23% | |
| 20Weak | Monopar Therapeutics | Raymond Anderson director | $352k 3,142 shares | -37% | |
| 32Weak | Monopar Therapeutics | Kim R Tsuchimoto Chief Financial Officer | $456k 4,090 shares | -100% | |
| 30Weak | Monopar Therapeutics | Raymond Anderson director | $351k 3,142 shares | -12% | |
| 0Weak | Monopar Therapeutics | Patrice Rioux other | $111 1 shares | -0% | |
| 48Moderate | MNPRbuy Monopar Therapeutics | Quan Anh Vu Chief Financial Officer | $105k 1,500 shares | - | |
| 40Moderate | MNPRsell Monopar Therapeutics | Arthur J Klausner director | $344k 5,121 shares | -37% | |
| 70Notable | MNPRsell Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $35M 550,229 shares | -67% | |
| 65Notable | Monopar Therapeutics | Chandler Robinson Chief Executive Officer | $672k 16,800 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.